Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology

Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology: A Multicenter Randomized Controlled Trial

At present, it is not clear whether performing a hip arthroscopy at the same time as a PAO improves patient outcomes after surgery compared to a PAO alone.

This research project will randomize patients to receive either a PAO alone, or a PAO and a hip arthroscopy at the same time.

Study Overview

• Status: Recruiting
• Conditions: Hip Dysplasia
• Intervention / Treatment: Procedure: PAO with hip arthroscopy; Procedure: PAO without hip arthroscopy

Detailed Description

Hip dysplasia is a developmental abnormality of the acetabulum (hip socket) that causes abnormal stresses inside the hip joint and leads to painful arthritis at a young age. Many patients develop painful symptoms in their hip before advanced arthritis occurs.

The periacetabular osteotomy (PAO) is a surgical procedure that reorients the acetabulum to reduce the stresses inside the hip joint. The PAO is very effective at improving symptoms and quality of life. However, some patients may have residual symptoms.

Frequently, people with hip dysplasia will have an MRI done before their surgery, which helps to identify other the abnormalities inside their hip joint (e.g., labral tears). These abnormalities inside the joint cannot easily be addressed through PAO alone, however they can be addressed with hip arthroscopy. Hip arthroscopy is a separate minimally invasive surgical procedure that allows the surgeon to access the inside of the hip joint with a small camera and address any abnormalities.

At present, it is not clear whether performing a hip arthroscopy at the same time as a PAO improves patient outcomes after surgery compared to a PAO alone.

This research project will randomize patients to receive either a PAO alone, or a PAO and a hip arthroscopy at the same time. Patients will be followed for 2 years after surgery. Symptomatic differences between the two patient groups will be assessed to determine added benefit of the hip arthroscopy.

• Study Type: Interventional
• Enrollment (Estimated): 204
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Cheryl Kreviazuk; Phone Number: 613-737-8920; Email: ckreviazuk@ohri.ca
• Study Contact Backup: Name: Geoffrey Wilkin, MD; Phone Number: 10347 613-798-5555; Email: gwilkin@toh.ca

Study Locations

• Canada
  • Québec, Canada, G1J 1Z4
    • Recruiting
    • CHU de Québec - Université Laval
    • Contact: Etienne Belzile, MD
  • Ontario
    • Ottawa, Ontario, Canada, K1H 8L1
      • Recruiting
      • Children's Hospital of Eastern Ontario
      • Contact: Kevin Smit, MD
    • Ottawa, Ontario, Canada, K1H8L6
      • Recruiting
      • Ottawa Hospital Research Institute
      • Contact: Geoffrey Wilkin, MD; Phone Number: 613-737-8920
      • Contact: Research Team; Phone Number: 613-737-8920
• United States
  • Illinois
    • Chicago, Illinois, United States, 60611
      • Recruiting
      • Northwestern University
      • Contact: Michael Stover, MD
  • Michigan
    • Royal Oak, Michigan, United States, 48073
      • Recruiting
      • William Beaumont Hospital
      • Contact: Ira Zaltz, MD
  • Missouri
    • Saint Louis, Missouri, United States, 63130
      • Recruiting
      • The Washington University
      • Contact: John C. Clohisy, MD
  • New York
    • New York, New York, United States, 10021
      • Recruiting
      • Hospital for Special Surgery
      • Contact: Ernest Sink, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 50 years (Child, Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Skeletally mature patient undergoing Bernese periacetabular osteotomy for symptomatic acetabular dysplasia/hip instability
• Pre-Operative MRI at 3T and/or gadolinium MR arthrogram
• Age, 16-50 years old
• Patient capable of giving informed consent

Exclusion Criteria:

• Prior hip/pelvis surgery of any kind on the surgical side
• Prior hip arthroplasty surgery on either side
• Radiographic evidence of arthritis (i.e. Tönnis grade =2)
• Known connective tissue disorder (e.g. Ehlers-Danlos Syndrome, etc.)
• Known neuromuscular disorder (e.g. Cerebral Palsy, Spina bifida, etc.)
• Known skeletal dysplasia (e.g. Achondroplasia, Multiple Epiphyseal Dysplasia, etc.)
• Cognitive impairment that prevents accurate completion of patient-reported outcome questionnaires.
• Patient unable/unwilling to complete all required follow-up visits
• Concurrent proximal femoral osteotomy and/or surgical hip dislocation

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: PAO with hip arthroscopy; Patient's in the "Scope PAO" group have been diagnosed with hip dysplasia and a decision has been made between the patient and the surgeon that the best way to treat the hip problems is with surgery. Patient's in the "Scope-PAO" group have been randomized to receive a periacetabular osteotomy with a hip arthroscopy.	Procedure: PAO with hip arthroscopy; Participants who are randomized to the Scope-PAO group will receive central compartment hip arthroscopy in addition to the PAO.
Active Comparator: PAO without hip arthroscopy; Patient's in the "PAO-only" group have been diagnosed with hip dysplasia and a decision has been made between the patient and the surgeon that the best way to treat the hip problems is with surgery. Patient's in the "PAO-only" group have been randomized to receive a periacetabular osteotomy only.	Procedure: PAO without hip arthroscopy; Participants who are randomized to the "PAO-only" group will receive a Bernese Periacetabular Osteotomy (PAO) for treatment of hip dysplasia.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
iHOT-33	Patient-reported quality of life will be the primary outcome used for comparison between the two treatment groups as measured by the International Hip Outcome Tool (iHOT-33). The iHOT-33 is a validated, self-administered quality of life assessment tool for young, active patients with hip symptoms.	24 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
HOOS	Hip-specific symptoms and functional impairment will be compared using the Hip Disability and Osteoarthritis Outcome Score (HOOS). This 40-item patient reported outcome tool has been validated for use in patients with and without hip osteoarthritis and has shown good responsiveness, reliability and reproducibility in this patient population.	before surgery, 6 months, 12 months, 24 months after surgery
PROMIS Global 10	Global Health assessment will be compared using the PROMIS Global 10 Score. This 10-item tool assesses general domains of health related quality of life in the domains of physical, mental, and social well-being.	before surgery, 6 months, 12 months, 24 months after surgery
Operative time	Total operative time is expected to be longer in the "Scope-PAO" treatment group, however the average increase in time will be valuable information for future research assessing cost-effectiveness of this treatment strategy. Total operative time will be measured from the time the patient enters the operating room to the time the patient is ready for transfer to post-anesthetic care unit (PACU). This time interval represents the best assessment of the overall time cost to the health care system associated with the surgical procedure while avoiding confounding due to delays in transfer to PACU.	intra-operative
Hospital Length of Stay	Length of stay, measured in days, will be assessed from date of admission to date of discharge up to one month.	up to one month
Adverse Events	Adverse events will be assessed prospectively at the first and second post-operative visits using Sink et al.'s classification system that grades the complications based on required treatment and long-term morbidity.	2-4 weeks and 3 months after surgery
Cost-Effectiveness	The cost-effectiveness of the two study groups will be assessed prospectively using the Work Productivity and Activity Impairment Questionnaire. This 6-item validated questionnaire quantifies work impairments. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism and percentage of impairment in activities performed outside of work. Greater scores indicate greater impairment.	6 months, 12 months, and 24 months after surgery

Collaborators and Investigators

• Sponsor: Ottawa Hospital Research Institute
• Investigators: Principal Investigator: Geoffrey Wilkin, MD, The Ottawa Hospital Research Institute

Publications and helpful links

General Publications

• Wilkin GP, Poitras S, Clohisy J, Belzile E, Zaltz I, Grammatopoulos G, Melkus G, Rakhra K, Ramsay T, Thavorn K, Beaule PE. Periacetabular osteotomy with or without arthroscopic management in patients with hip dysplasia: study protocol for a multicenter randomized controlled trial. Trials. 2020 Aug 18;21(1):725. doi: 10.1186/s13063-020-04592-9.

Study record dates

Study Major Dates

• Study Start (Actual): April 4, 2018
• Primary Completion (Estimated): December 31, 2024
• Study Completion (Estimated): December 31, 2024

Study Registration Dates

• First Submitted: March 15, 2018
• First Submitted That Met QC Criteria: March 21, 2018
• First Posted (Actual): March 29, 2018

Study Record Updates

• Last Update Posted (Actual): January 5, 2024
• Last Update Submitted That Met QC Criteria: January 2, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Wounds and Injuries; Congenital Abnormalities; Joint Diseases; Musculoskeletal Diseases; Hip Injuries; Musculoskeletal Abnormalities; Joint Dislocations; Hip Dislocation; Developmental Dysplasia of the Hip; Hip Dislocation, Congenital
• Other Study ID Numbers: 20170796

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No